CA3001962A1 - Traitement d'une grippe moderee a grave - Google Patents
Traitement d'une grippe moderee a grave Download PDFInfo
- Publication number
- CA3001962A1 CA3001962A1 CA3001962A CA3001962A CA3001962A1 CA 3001962 A1 CA3001962 A1 CA 3001962A1 CA 3001962 A CA3001962 A CA 3001962A CA 3001962 A CA3001962 A CA 3001962A CA 3001962 A1 CA3001962 A1 CA 3001962A1
- Authority
- CA
- Canada
- Prior art keywords
- asa
- composition
- influenza
- use according
- lasag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 206010022000 influenza Diseases 0.000 title claims description 90
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 112
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 109
- 208000024891 symptom Diseases 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 23
- 230000009385 viral infection Effects 0.000 claims abstract description 21
- 206010011224 Cough Diseases 0.000 claims abstract description 16
- 208000000112 Myalgia Diseases 0.000 claims abstract description 13
- 206010016256 fatigue Diseases 0.000 claims abstract description 12
- 206010019233 Headaches Diseases 0.000 claims abstract description 11
- 206010068319 Oropharyngeal pain Diseases 0.000 claims abstract description 11
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 11
- 231100000869 headache Toxicity 0.000 claims abstract description 11
- 206010028735 Nasal congestion Diseases 0.000 claims abstract description 10
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000003434 inspiratory effect Effects 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 6
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 claims description 4
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 241000713196 Influenza B virus Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 230000000694 effects Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 230000002411 adverse Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 229960003752 oseltamivir Drugs 0.000 description 5
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010043521 Throat irritation Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- -1 LASAG Chemical class 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005315 distribution function Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229940124818 soft mist inhaler Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010063880 Vessel puncture site reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229940066366 other cough suppressants in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 108010029853 transcription factor nuclear factor 1 Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un composé, à savoir de l'acide acétylsalicylique (ASA) ou un sel pharmaceutiquement acceptable de celui-ci, ou une composition pharmaceutique comprenant de l'ASA ou un sel pharmaceutiquement acceptable de celui-ci, destinés à être utilisés dans le traitement d'un patient, par exemple d'un être humain, souffrant d'une infection grave par le virus de la grippe et/ou d'un symptôme ou d'un état associé à celle-ci (à savoir, une congestion nasale, une angine, une toux, de la fièvre, une fatigue, des céphalées et des myalgies), ladite utilisation comprenant l'administration par inhalation au patient d'une composition comprenant de l'ASA ou un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202212 | 2015-12-22 | ||
| EP15202212.5 | 2015-12-22 | ||
| PCT/EP2016/082307 WO2017109037A1 (fr) | 2015-12-22 | 2016-12-22 | Traitement d'une grippe modérée à grave |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3001962A1 true CA3001962A1 (fr) | 2017-06-29 |
| CA3001962C CA3001962C (fr) | 2022-09-13 |
Family
ID=55022370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3001962A Active CA3001962C (fr) | 2015-12-22 | 2016-12-22 | Traitement d'une grippe moderee a grave |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11376265B2 (fr) |
| EP (1) | EP3393517B1 (fr) |
| JP (1) | JP7369523B2 (fr) |
| CN (1) | CN108472375A (fr) |
| AU (1) | AU2016378478B2 (fr) |
| CA (1) | CA3001962C (fr) |
| DK (1) | DK3393517T3 (fr) |
| ES (1) | ES2894330T3 (fr) |
| PT (1) | PT3393517T (fr) |
| WO (1) | WO2017109037A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3044137C (fr) * | 2016-12-23 | 2021-06-15 | Ventaleon Gmbh | Synthese amelioree de particules d'acetylsalicylate de lysine · glycine |
| KR20220050932A (ko) * | 2019-08-22 | 2022-04-25 | 어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 | 비-스테로이드성 항-염증 약물을 사용한 조성물 및 방법 |
| GB202003722D0 (en) * | 2020-03-14 | 2020-04-29 | Martin John Francis | Treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19851279B4 (de) * | 1998-06-17 | 2006-05-24 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | Vorrichtung zum gesteuerten inhalatorischen Einbringen von dosierten Medikamenten in die Lunge |
| DE19912461B4 (de) * | 1999-03-19 | 2006-07-20 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | Vorrichtung zur Flußbegrenzung bei niedrigen Differenzdrücken |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| DE102008004386A1 (de) * | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
| US8668901B2 (en) * | 2009-02-04 | 2014-03-11 | Activaero Gmbh Research & Development | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma |
| AU2013388034B2 (en) * | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| CA3076353A1 (fr) * | 2017-09-22 | 2019-03-28 | Otitopic Inc. | Compositions de poudre seche contenant du stearate de magnesium |
-
2016
- 2016-12-22 PT PT168230027T patent/PT3393517T/pt unknown
- 2016-12-22 ES ES16823002T patent/ES2894330T3/es active Active
- 2016-12-22 CA CA3001962A patent/CA3001962C/fr active Active
- 2016-12-22 US US16/065,600 patent/US11376265B2/en active Active
- 2016-12-22 JP JP2018533677A patent/JP7369523B2/ja active Active
- 2016-12-22 WO PCT/EP2016/082307 patent/WO2017109037A1/fr not_active Ceased
- 2016-12-22 AU AU2016378478A patent/AU2016378478B2/en active Active
- 2016-12-22 CN CN201680068680.8A patent/CN108472375A/zh active Pending
- 2016-12-22 EP EP16823002.7A patent/EP3393517B1/fr active Active
- 2016-12-22 DK DK16823002.7T patent/DK3393517T3/da active
-
2022
- 2022-06-16 US US17/807,184 patent/US20220387455A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2894330T8 (es) | 2023-02-14 |
| WO2017109037A1 (fr) | 2017-06-29 |
| CN108472375A (zh) | 2018-08-31 |
| US11376265B2 (en) | 2022-07-05 |
| EP3393517A1 (fr) | 2018-10-31 |
| EP3393517B1 (fr) | 2021-08-11 |
| JP2019504040A (ja) | 2019-02-14 |
| DK3393517T3 (da) | 2021-11-01 |
| PT3393517T (pt) | 2021-10-19 |
| US20220387455A1 (en) | 2022-12-08 |
| JP7369523B2 (ja) | 2023-10-26 |
| CA3001962C (fr) | 2022-09-13 |
| AU2016378478A1 (en) | 2018-05-10 |
| ES2894330T3 (es) | 2022-02-14 |
| AU2016378478B2 (en) | 2021-11-25 |
| US20190134066A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220387455A1 (en) | Treatment of moderate to severe influenza | |
| JP2020002144A (ja) | 小児における急性呼吸促迫症候群の治療のための吸入一酸化窒素ガスを使用する方法 | |
| AU2010335594B2 (en) | Synergistic antiviral composition and use thereof | |
| US20150231133A1 (en) | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation | |
| Mancuso et al. | Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| US20220025019A1 (en) | Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin | |
| CN115867288A (zh) | 用于治疗呼吸系统病症的组合物 | |
| US12171732B2 (en) | Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections | |
| Van Wyk | The common cold and influenza: colds & flu | |
| CN103169970A (zh) | 一种治疗病毒性肺炎的药物组合物 | |
| US20230310544A1 (en) | ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG | |
| JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| EP3906934A1 (fr) | Application de dalargine pour la prévention d'infections virales des voies respiratoires et la prévention du développement de complications lors d'infections virales des voies respiratoires | |
| WO2025104696A1 (fr) | Composition pharmaceutique comprenant de l'édaravone destinée à être utilisée dans la réduction des taux de marqueurs inflammatoires de l'il-6 et du tnf-alpha et la réduction du temps de retrait de l'oxygénothérapie chez des patients atteints de maladies infectieuses | |
| US20230310467A1 (en) | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | |
| WO2022145407A1 (fr) | Médicament comprenant un antagoniste de dp1 et un inhibiteur de la neuraminidase destiné au traitement d'infections virales des voies respiratoires | |
| HK1174835A (en) | Synergistic antiviral composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210922 |
|
| EEER | Examination request |
Effective date: 20210922 |